glp 1 approved for nash Possible hepatoprotective effects of GLP-1 receptor agonists mash and glp 1 Novo's

Genetic testing: We evaluate genes, including polygenic risk scores, MTHFR, ApoE (Alzheimers and cardiovascular risk), Factor V and II (clotting risk), and 9p21 (heart disease marker)

1%), and dyspnea (3/358

Based on these insights, customized therapy orders are created, ensuring that each patient receives the most effective treatment plan

the dual GIP/GLP-1 agonism of tirzepatide produces greater triglyceride and VLDL reduction than GLP-1 agonism alone, suggesting the GIP component contributes to the lipid effect

Stronger Antioxidant Defense: The combination offers enhanced protection against free radicals, reducing visible signs of aging and environmental skin stress